ClinicalTrials.gg
CompletedNCT02892409Updated Jan 3, 2019Results posted

TAK-438 Bismuth Drug Interaction Study

A Phase 1 interventional study of Clarithromycin and Amoxicillin in Helicobacter Pylori, sponsored by Takeda. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-01-03.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years to 60 Years
Sex
All
01

Study summary

To evaluate the safety, tolerability, and pharmacokinetics (PK) of quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole.

Read the detailed description

This is a phase 1, double-blind, parallel group study in participants with Helicobacter pylori (HP positive) who are, additionally, cytochrome P-450 (CYP)2C19 extensive metabolizers (EM) to evaluate the safety, tolerability and pharmacokinetics (PK) of a quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole. The study will enroll 30 participants.

The treatment phase consists of quadruple therapy twice daily (BID) with tripotassium bismuth dicitrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and TAK-438 (20 mg) (Group B) or quadruple therapy BID with tripotassium bismuth dicitrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg),and lansoprazole (30 mg) (Group A) from Days 1 to 14. Participants will be discharged on Day 15 after final PK blood samples are collected and all procedures performed.

This single-center will be conducted in Korea. Participants will remain confined to the study site from check-in (Day -1) through Day 15 and will followed up through call on Day 17 and return on Day 42 for a follow-up assessment.

02

Conditions studied

  • Helicobacter Pylori

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. HP positive participants.
  2. Has between greater than (>) 18 and less than equal to (\<=) 30 kilogram per square meter (kg/m\^2) and weighs greater than equal to (>=) 50 kilogram (kg).
  3. Is willing to abstain from strenuous exercise from 72 hours before first dose (Day 1) until the Follow-up call on Day 17.

Exclusion criteria

Exclusion Criteria:

  1. Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day -1).
  2. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular consumption of 21 units or more units per week) at any time prior to the Screening Visit or is unwilling to agree to abstain from alcohol and drugs throughout the study (up to Day 17).
  3. Has history of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive esophagitis, duodenal ulcer, gastric ulcer, Barrett's esophagus, or Zollinger-Ellison syndrome.
  4. Has undergone therapeutic upper gastrointestinal endoscopic therapy (example, endoscopic hemostasis or excision including ) within 30 days prior to Screening.
  5. Has undergone major surgical procedures within the past 1 month or are scheduled to undergo surgical procedures that may affect gastric acid secretion (example, abdominal surgery, vagotomy, or craniotomy).
  6. Has a history of cancer, except basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has been in remission for at least 5 years prior to Day 1.
  7. Has a positive test result for surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody/antigen at Screening.
  8. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 6 weeks prior to Check-in. Cotinine test is positive at Screening or Check-in.
  9. Has poor peripheral venous access. Has donated or lost 450 milliliter (mL) or more of his blood volume (including plasmapheresis), or had a transfusion of any blood product within 90 days prior to Day 1.
  10. Has abnormal Screening or Check-in laboratory values that suggest a underlying disease or subject with the following laboratory abnormalities: (ALT), aspartate aminotransferase (AST) or total > the (ULN).
  11. Has reduced renal function assessed by having an estimated \<90 milliliter per min per 1.73 square meter (mL/min/1.73 m\^2) (as estimated by Chronic Kidney Disease-Epidemology Collaboration) at Screening or Check-in.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Clarithromycin + Amoxicillin + Bismuth + Lansoprazole

    Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and lansoprazole 30 mg, capsules, orally, twice daily on Days 1 to 14.

    Drug: Clarithromycin · Drug: Amoxicillin · Drug: Tripotassium bismuth dicitrate · Drug: Lansoprazole

  • Experimental
    Clarithromycin + Amoxicillin + Bismuth + TAK-438

    Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and TAK-438 20 mg, tablets, orally, twice daily on Days 1 to 14.

    Drug: Clarithromycin · Drug: Amoxicillin · Drug: Tripotassium bismuth dicitrate · Drug: TAK-438

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)

    Time frame: Baseline up to Day 17

  2. Percentage of Participants Who Discontinue Due to an Adverse Event (AE)

    Time frame: Baseline up to Day 17

  3. Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-dose

    Time frame: Baseline up Day 15

  4. Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose

    Time frame: Baseline up to Day 15

  5. Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose

    Time frame: Baseline up to Day 15

  6. Cmax: Maximum Observed Plasma Concentration for Bismuth

    Time frame: Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose

  7. AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Bismuth

    Time frame: Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose

  8. Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for Bismuth

    Time frame: Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose

07

Results

Posted Jan 3, 2019

Participant flow

Participants took part in the study at 1 investigative site in Korea from 05 September 2016 to 11 May 2017.

Participant flow — Overall Study
MilestoneClarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + Lansoprazole
Started1515
Completed1214
Not completed31
Withdrew: Adverse event10
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryPercentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
Time frame:
Baseline up to Day 17
Reported as:
Number · percentage of participants
Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
percentage of participantsClarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + Lansoprazole
Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)53.366.7
PrimaryPercentage of Participants Who Discontinue Due to an Adverse Event (AE)
Time frame:
Baseline up to Day 17
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinue Due to an Adverse Event (AE)
percentage of participantsClarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + Lansoprazole
Percentage of Participants Who Discontinue Due to an Adverse Event (AE)6.70.0
PrimaryPercentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-dose
Time frame:
Baseline up Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-dose
percentage of participantsClarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + Lansoprazole
Amylase (greater than [>] 2*upper limit of normal)0.06.7
Potassium (>6.0 millimole per liter [mmol/L])0.06.7
PrimaryPercentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose
Time frame:
Baseline up to Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose
percentage of participantsClarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + Lansoprazole
Body temperature (less than [<] 35.6 celsius [C])0.06.7
Body temperature (>37.7 C)6.76.7
Systolic blood pressure(<85 millimeter of mercury)6.76.7
Diastolic blood pressure(<50millimeter of mercury)6.76.7
PrimaryPercentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose
Time frame:
Baseline up to Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose
percentage of participantsClarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + Lansoprazole
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose0.06.7
PrimaryCmax: Maximum Observed Plasma Concentration for Bismuth
Time frame:
Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose
Reported as:
Mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for Bismuth
nanogram per milliliter (ng/mL)Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + Lansoprazole
Cmax: Maximum Observed Plasma Concentration for Bismuth28.08 ± 11.69130.14 ± 24.612
Statistical analysis
  • Clarithromycin + Amoxicillin + Bismuth + TAK-438 vs Clarithromycin + Amoxicillin + Bismuth + Lansoprazole · Least square (ls) mean ratio: 105.1 · 95% CI 66.051 to 167.183
PrimaryAUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Bismuth
Time frame:
Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose
Reported as:
Mean · hours nanogram per milliliter (h*ng/mL)
AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Bismuth
hours nanogram per milliliter (h*ng/mL)Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + Lansoprazole
AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Bismuth103.0 ± 37.498111.1 ± 45.010
Statistical analysis
  • Clarithromycin + Amoxicillin + Bismuth + TAK-438 vs Clarithromycin + Amoxicillin + Bismuth + Lansoprazole · Ls mean ratio: 93.6 · 95% CI 67.137 to 130.569
PrimaryAeτ: Amount of Drug Excreted in Urine During a Dosing Interval for Bismuth
Time frame:
Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose
Reported as:
Mean · nanogram (ng)
Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for Bismuth
nanogram (ng)Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + Lansoprazole
Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for Bismuth497300 ± 202270537600 ± 188340

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and up to Day 17. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clarithromycin + Amoxicillin + Bismuth + TAK-4380/15 (0%)0/15 (0%)8/15 (53.3%)
Clarithromycin + Amoxicillin + Bismuth + Lansoprazole0/15 (0%)0/15 (0%)10/15 (66.7%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventClarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + Lansoprazole
DysgeusiaNervous system disorders0/153/15
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/153/15
HyperhidrosisSkin and subcutaneous tissue disorders3/151/15
Faeces discolouredGastrointestinal disorders1/152/15
Feeling hotGeneral disorders2/151/15
PalpitationsCardiac disorders1/150/15
HyperthyroidismEndocrine disorders1/150/15
Eye pruritusEye disorders0/151/15
DiarrhoeaGastrointestinal disorders1/151/15
DyspepsiaGastrointestinal disorders1/150/15

Baseline characteristics

The safety analysis set included all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + LansoprazoleTotal
Mean32.8 ± 6.8733.3 ± 8.6133.1 ± 7.66
Sex: Female, Male
Sex: Female, Male(Participants)Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + LansoprazoleTotal
Female112
Male141428
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + LansoprazoleTotal
American Indian or Alaska Native000
Asian151530
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Height
Height(centimeter (cm))Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + LansoprazoleTotal
Mean173.7 ± 5.04168.9 ± 5.14171.3 ± 5.56
Weight
Weight(kilogram (kg))Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + LansoprazoleTotal
Mean72.41 ± 5.02866.05 ± 8.39569.23 ± 7.528
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + LansoprazoleTotal
Mean24.03 ± 1.79523.13 ± 2.27123.58 ± 2.064
Smoking Classification
Smoking Classification(Participants)Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + LansoprazoleTotal
Never smoked141226
Ex-smoker134
Alcohol Consumption
Alcohol Consumption(Participants)Clarithromycin + Amoxicillin + Bismuth + TAK-438Clarithromycin + Amoxicillin + Bismuth + LansoprazoleTotal
Drank a couple of days per week202
Drank a couple of days per month4610
Never Drank9918

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Seoul, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Apr 2017, 7 months.

Results were first posted in Jan 2019, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2016
First posted
Sep 8, 2016
StartActual
Sep 5, 2016
Primary completionActual
Apr 17, 2017
CompletionActual
May 11, 2017
Results first posted
Jan 3, 2019
Last update
Jan 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02892409
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 8, 2016
Start date
Sep 5, 2016
Primary completion
Apr 17, 2017
Completion
May 11, 2017
Results posted
Jan 3, 2019
Last update
Jan 3, 2019

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amoxicillin · Vonoprazan

Start the discussion